Literature DB >> 17110796

Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model.

Valérie Bertaina-Anglade1, Christophe Drieu la Rochelle, Pierre-Alain Boyer, Elisabeth Mocaër.   

Abstract

To confirm the antidepressant-like activity of agomelatine (S 20098), a melatonin agonist and 5-hydroxytryptamine2C antagonist, already reported in the chronic mild stress and forced swimming tests, the effects of agomelatine were investigated in the learned helplessness test and compared with those of imipramine, melatonin and a selective 5-hydroxytryptamine2C antagonist, SB-242 084. Agomelatine was administered for 5 days either once a day or twice a day, and the effects of pretreatment by a melatonin receptor antagonist, S 22153 (20 mg/kg/day), were studied. A deficit in avoidance learning was observed in helpless control animals. Agomelatine (10 mg/kg/day) administered once a day significantly reduced this deficit with an effect similar to that of imipramine. Effects of agomelatine were abolished by S 22153 pretreatment. Melatonin or SB-242 084 did not reduce the deficit of helpless control animals. These results confirm the antidepressant-like activity of agomelatine and suggest a role of melatonin receptors in its mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17110796     DOI: 10.1097/FBP.0b013e3280116e5c

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  25 in total

1.  The effect of agomelatine on 5HT(2C) receptors in humans: a clinically relevant mechanism?

Authors:  Trevor R Norman
Journal:  Psychopharmacology (Berl)       Date:  2012-02-15       Impact factor: 4.530

Review 2.  New therapeutic targets for mood disorders.

Authors:  Rodrigo Machado-Vieira; Giacomo Salvadore; Nancy DiazGranados; Lobna Ibrahim; David Latov; Cristina Wheeler-Castillo; Jacqueline Baumann; Ioline D Henter; Carlos A Zarate
Journal:  ScientificWorldJournal       Date:  2010-04-13

Review 3.  New targets for rapid antidepressant action.

Authors:  Rodrigo Machado-Vieira; Ioline D Henter; Carlos A Zarate
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 4.  MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.

Authors:  Jiabei Liu; Shannon J Clough; Anthony J Hutchinson; Ekue B Adamah-Biassi; Marina Popovska-Gorevski; Margarita L Dubocovich
Journal:  Annu Rev Pharmacol Toxicol       Date:  2015-10-23       Impact factor: 13.820

5.  Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models.

Authors:  Shao-wen Tian; Moshe Laudon; Li Han; Jun Gao; Fu-lian Huang; Yu-feng Yang; Hai-feng Deng
Journal:  Acta Pharmacol Sin       Date:  2010-06-28       Impact factor: 6.150

6.  Blockade of stress-induced increase of glutamate release in the rat prefrontal/frontal cortex by agomelatine involves synergy between melatonergic and 5-HT2C receptor-dependent pathways.

Authors:  Daniela Tardito; Marco Milanese; Tiziana Bonifacino; Laura Musazzi; Massimo Grilli; Alessandra Mallei; Elisabeth Mocaer; Cecilia Gabriel-Gracia; Giorgio Racagni; Maurizio Popoli; Giambattista Bonanno
Journal:  BMC Neurosci       Date:  2010-06-03       Impact factor: 3.288

Review 7.  Bipolar disorder: candidate drug targets.

Authors:  Carlos A Zarate; Husseini K Manji
Journal:  Mt Sinai J Med       Date:  2008 May-Jun

Review 8.  Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new?

Authors:  R Jockers; P Maurice; J A Boutin; P Delagrange
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

9.  Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.

Authors:  Franck Chenu; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

10.  Chronic agomelatine treatment corrects behavioral, cellular, and biochemical abnormalities induced by prenatal stress in rats.

Authors:  Sara Morley-Fletcher; Jerome Mairesse; Amelie Soumier; Mounira Banasr; Francesca Fagioli; Cecilia Gabriel; Elisabeth Mocaer; Annie Daszuta; Bruce McEwen; Ferdinando Nicoletti; Stefania Maccari
Journal:  Psychopharmacology (Berl)       Date:  2011-04-19       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.